IF 1.9 4区医学

Lupus Pub Date : 2024-11-01 Epub Date: 2024-09-27 DOI: 10.1177/09612033241286601

Camila de Oliveira Vaz, Bruna Cardoso Jacintho, Gabrielle de Mello Santos, José Diogo de Oliveira, Bruna Moraes Mazetto, Murilo Vieira Geraldo, Fernanda A Orsi

{"title":"Identification of common MicroRNAs expression signatures in antiphospholipid syndrome and thromboembolic disease: A scoping review.","authors":"Camila de Oliveira Vaz, Bruna Cardoso Jacintho, Gabrielle de Mello Santos, José Diogo de Oliveira, Bruna Moraes Mazetto, Murilo Vieira Geraldo, Fernanda A Orsi","doi":"10.1177/09612033241286601","DOIUrl":"10.1177/09612033241286601","url":null,"abstract":"Background: Antiphospholipid syndrome (APS) is an acquired autoimmune disorder characterized by distinct pathophysiological mechanisms leading to heterogeneous manifestations, including venous and arterial thrombosis. Despite the lack of specific markers of thrombosis risk in APS, some of the mechanisms responsible for thrombosis in APS may overlap with those of other thromboembolic diseases. Understanding these similarities is important for improving the assessment of thrombosis risk in APS. MicroRNAs (MiRNAs) are RNA molecules that regulate gene expression and may influence the autoimmune response and coagulation.Purpose: In this scoping review we aimed to investigate shared miRNAs profiles associated with APS and other thromboembolic diseases as a means of identifying markers indicative of a pro-thrombotic profile among patients with APS.Data collection and results: Through a comprehensive search of scientific databases, 45 relevant studies were identified out of 1020 references. miRs-124-3p, 125b-5p, 125a-5p, and 17-5p, were associated with APS and arterial thrombosis, while miRs-106a-5p, 146b-5p, 15a-5p, 222-3p, and 451a were associated with APS and venous thrombosis. Additionally, miR-126a-3p was associated with APS and both arterial and venous thrombosis.Conclusion: We observed that APS shares a common miRNAs signature with non-APS related thrombosis, suggesting that miRNA expression profiles may serve as markers of thrombotic risk in APS. Further validation of a pro-thrombotic miRNA signature in APS is warranted to improve risk assessment, diagnosis, and management of APS.","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1455-1465"},"PeriodicalIF":1.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optical coherence tomography angiography findings of systemic lupus erythematosus patients and the effect of neuropsychiatric involvement on it. 系统性红斑狼疮患者的光学相干断层血管造影检查结果以及神经精神疾病对其的影响。

IF 1.9 4区医学

Lupus Pub Date : 2024-11-01 Epub Date: 2024-09-05 DOI: 10.1177/09612033241283091

Kevser Koyuncu, Selime Ermurat

{"title":"Optical coherence tomography angiography findings of systemic lupus erythematosus patients and the effect of neuropsychiatric involvement on it.","authors":"Kevser Koyuncu, Selime Ermurat","doi":"10.1177/09612033241283091","DOIUrl":"10.1177/09612033241283091","url":null,"abstract":"Aim: To investigate the radial peripapillary capillary plexus vessel density (RPCP-VD) and peripapillary retinal nerve fiber layer thickness (pRNFLT) of systemic lupus erythematosus (SLE) and neuropsychiatric SLE patients (NPSLE) using disc optical coherence tomography angiography (OCTA) and investigate the association between these parameters and SLE disease activity index (SLEDAI-2K).Methods: A total of 64 'right eyes (36 SLE patients, 28 healthy controls (HCs)) were included in this cross-sectional case-control study. Ten (27.7%) patients had neuropsychiatric involvement. RPCP-VD and pRNFLT of patients were evaluated in all peripapillary sectors. RPCP-VD and pRNFLT of NPSLE, non-NPSLE, and HCs were compared. The correlation between SLEDAI-2K and OCTA findings was evaluated.Results: SLE patients' RPCP-VDs were significantly lower compared with the HCs except for two sectors (p < .005). There was not a significant difference in pRNFLT of SLE patients and HCs. There was not a correlation between SLEDAI-2K and RPCP-VD in any subsectors but there was a significantly negative correlation between pRNFLT in tempo-inferior and inferior-temporal sectors. When compared with non-NPSLE-patients, NPSLE patients had significantly lower inferior-hemi (p = .001), inferior-nasal VDs (p = .003), and peripapillary (p = .012), superior-hemi (p = .038), inferior-hemi (p = .026), inferior-nasal (p = .002) and inferior-temporal (p = .012) pRNFLTs. A negative correlation was found between NPSLE and pRNFLT.Conclusion: SLE patients may have early subclinical vascular involvement leading to decreased RPCP-VD. A negative correlation between the SLEDAI-2K and pRNFLT in the temporal subsectors of all SLE patients may show an association between the disease activity and temporal pRNFL thinning. The presence of neuropsychiatric involvement may also be associated with decreased RPCP-VD and pRNFLT.","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1424-1434"},"PeriodicalIF":1.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JAK inhibitors in systemic lupus erythematosus: Translating pathogenesis into therapy. 系统性红斑狼疮中的 JAK 抑制剂：将发病机制转化为疗法。

IF 1.9 4区医学

Lupus Pub Date : 2024-11-01 Epub Date: 2024-10-09 DOI: 10.1177/09612033241287594

Gabriela Ceobanu, Christopher J Edwards

{"title":"JAK inhibitors in systemic lupus erythematosus: Translating pathogenesis into therapy.","authors":"Gabriela Ceobanu, Christopher J Edwards","doi":"10.1177/09612033241287594","DOIUrl":"10.1177/09612033241287594","url":null,"abstract":"Systemic lupus erythematosus (SLE) is a complex multi-organ autoimmune disease marked by the production of autoantibodies against nuclear structures, formation of immune complexes, and chronic inflammation triggered by their tissular deposition. SLE is characterized by alternating periods of relapse and remission and each flare has the potential to cause new organ damage related to either the disease process or the medication toxicity. Despite remarkable progress across its multiple domains, SLE is still an area with many unmet needs, calling for innovative and practical solutions. The efforts of the drug development programme in lupus have led to considerable growth in the last decade, owing to the approval of belimumab, anifrolumab, and voclosporin. The increasing understanding of the pathogenesis of the disease has enabled the exploration of novel therapeutic strategies. New discoveries in the intricate cytokine kaleidoscope of lupus have made the concept of targeted therapy an attractive and promising research focus. JAK inhibitors are oral targeted therapies approved for a wide variety of diseases across the Rheumatology, Gastroenterology, Dermatology, and Haematology fields. Multiple JAKis are currently being investigated in SLE. This paper aims to summarize existing data coming from both clinical trials and case reports regarding the use of JAK inhibitors in SLE.","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1403-1415"},"PeriodicalIF":1.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using linked electronic medical record-pharmacy data to examine lupus medication adherence: A retrospective cohort study. 利用电子病历与药房的关联数据研究狼疮患者的服药依从性：一项回顾性队列研究。

IF 1.9 4区医学

Lupus Pub Date : 2024-10-01 Epub Date: 2024-09-03 DOI: 10.1177/09612033241280695

Kai Sun, Daniel Wojdyla, Ankoor Shah, Amanda M Eudy, Megan Eb Clowse

{"title":"Using linked electronic medical record-pharmacy data to examine lupus medication adherence: A retrospective cohort study.","authors":"Kai Sun, Daniel Wojdyla, Ankoor Shah, Amanda M Eudy, Megan Eb Clowse","doi":"10.1177/09612033241280695","DOIUrl":"10.1177/09612033241280695","url":null,"abstract":"Introduction: Medication nonadherence is common in systemic lupus erythematosus (SLE) and associated with morbidity and mortality. We explored the reliability of pharmacy data within the electronic medical record (EMR) to examine factors associated with nonadherence to SLE medications.Methods: We included patients with SLE who were prescribed ≥1 SLE medication for ≥90 days. We compared two datasets of pharmacy fill data, one within the EMR and another from the vendor who obtained this information from pharmacies and prescription benefit managers. Adherence was defined by medication possession ratio (MPR) ≥80%. In addition to MPR for each SLE medication, we evaluated the weighted-average MPR and the proportion of patients adherent to ≥1 SLE medication and to all SLE medications. We used logistic regression to examine factors associated with adherence.Results: Among 181 patients (median age 36, 96% female, 58% Black), 98% were prescribed hydroxychloroquine, 34% azathioprine, 33% mycophenolate, 18% methotrexate, and 7% belimumab. Among 1276 pharmacy records, 74% overlapped between linked EMR-pharmacy data and data obtained directly from the vendor. Only 9% were available from the vendor but not through linked EMR-pharmacy data. The weighted-average MPR was 57%; 45% were adherent to hydroxychloroquine, 46% to ≥1 SLE medication, and 32% to all SLE medications. Older age was associated with adherence in univariable and multivariable analyses.Discussion: Our study showed that obtaining linked EMR-pharmacy data is feasible with minimal missing data and can be leveraged in future adherence research. Younger patients were more likely to be nonadherent and may benefit from targeted intervention.","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1299-1305"},"PeriodicalIF":1.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Macrophage activation syndrome as a presenting feature in juvenile systemic lupus erythematosus. 作为幼年系统性红斑狼疮一种表现特征的巨噬细胞活化综合征。

IF 1.9 4区医学

Lupus Pub Date : 2024-10-01 Epub Date: 2024-08-07 DOI: 10.1177/09612033241272972

Ishwarya Ramadoss, Pirahalathan Rengabashyam, Mythili Seetharaman Varadhan, Arul R Ponniah Subramanian

引用次数: 0

Treatment patterns in patients with systemic lupus erythematosus in New Zealand. 新西兰系统性红斑狼疮患者的治疗模式。

IF 1.9 4区医学

Lupus Pub Date : 2024-10-01 Epub Date: 2024-08-16 DOI: 10.1177/09612033241274911

Chunhuan Lao, Philippa Van Dantzig, Nikki Tugnet, Ross Lawrenson, Douglas White

{"title":"Treatment patterns in patients with systemic lupus erythematosus in New Zealand.","authors":"Chunhuan Lao, Philippa Van Dantzig, Nikki Tugnet, Ross Lawrenson, Douglas White","doi":"10.1177/09612033241274911","DOIUrl":"10.1177/09612033241274911","url":null,"abstract":"Objectives: This study aims to explore the treatment pattern of systemic lupus erythematosus (SLE) in Aotearoa/New Zealand.Methods: SLE patients were linked to the pharmaceutical dispensing data. The use of publicly funded anti-malarials, immunomodulators, biologics, glucocorticoids and bisphosphonates were compared by gender, ethnicity, age group, socioeconomic status and year of SLE identification. Adherence to hydroxychloroquine was examined using the medication possession ratio (MPR), with a MPR of ≥0.8 considered as high adherence.Results: Of the 2631 SLE patients, 73.8% used hydroxychloroquine, 64.1% used immunomodulators/biologics and 68.0% used 5 mg or more prednisone daily for at least 90 days. Women were more likely to use hydroxychloroquine than men. Asian patients had a different treatment pattern than other ethnic groups, and Māori were less likely to use hydroxychloroquine. The proportions of patients using different treatments decreased with age. Of the patients using hydroxychloroquine, 54.5% had high adherence. For patients over 40 years old and on long term prednisone, 47.3% had bisphosphonates and this figure was 17.8% for patients under the age of 40 years old. Patients with better socioeconomic status had a higher probability of using bisphosphonates than patients with lower socioeconomic status.Conclusions: Adherence to hydroxychloroquine in these patients varied and was lower in men and in Māori. Prednisone is commonly prescribed and used long term. Half of those over the age of 40 years old co-administered bisphosphonate. Further research is needed to identify the reasons for these discrepancies on SLE treatments by gender, ethnicity, age and socioeconomic status.","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1260-1273"},"PeriodicalIF":1.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11420593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gut microbiome composition and intestinal immunity in antiphospholipid syndrome patients versus healthy controls. 抗磷脂综合征患者与健康对照组的肠道微生物组组成和肠道免疫力。

IF 1.9 4区医学

Lupus Pub Date : 2024-10-01 Epub Date: 2024-08-17 DOI: 10.1177/09612033241274515

Valérie Lbi Jansen, Mark Davids, Dagmar Jm van Mourik, Johannes Hm Levels, Michiel Coppens, Saskia Middeldorp, Max Nieuwdorp, Thijs E van Mens

{"title":"Gut microbiome composition and intestinal immunity in antiphospholipid syndrome patients versus healthy controls.","authors":"Valérie Lbi Jansen, Mark Davids, Dagmar Jm van Mourik, Johannes Hm Levels, Michiel Coppens, Saskia Middeldorp, Max Nieuwdorp, Thijs E van Mens","doi":"10.1177/09612033241274515","DOIUrl":"10.1177/09612033241274515","url":null,"abstract":"Introduction: The gut microbiome is recognized as a factor that could potentially contribute to the persistent antibodies of antiphospholipid syndrome (APS). Gut microbial interventions can both induce and mitigate APS in mice. In human APS patients, anti-beta-2-glycoprotein I (β2GP-1) titers correlate with antibody titers against a gut commensal protein homologous to β2GP-1.Aim: To investigate the effect of the intestinal microenvironment on human APS. Methods We cross-sectionally compared intestinal microbiota composition quantified by shotgun sequencing; fecal short chain fatty acids (SCFAs), bacterial metabolites known to affect autoimmune processes; and fecal calprotectin, an intestinal inflammatory marker, in APS patients and healthy controls.Results: Neither alpha nor beta diversity of the gut microbiota differed between APS patients (n = 15) and controls (n = 16) and no taxa were differentially abundant. Moreover, fecal SCFAs and fecal calprotectin, did not differ between the groups.Conclusion: Gut microbiome effects on the APS phenotype are likely not driven by bacterial overabundance, SCFA production or intestinal inflammation.","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1373-1378"},"PeriodicalIF":1.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of survivin expression and regulating miRNAs of survivin expression in peripheral blood mononuclear cells in systemic lupus erythematous patients. 评估系统性红斑狼疮患者外周血单核细胞中存活素的表达和调控存活素表达的 miRNAs。

IF 1.9 4区医学

Lupus Pub Date : 2024-10-01 Epub Date: 2024-08-20 DOI: 10.1177/09612033241276280

Nasim Bolouri, Reza Mansouri, Elham Farhadi, Samaneh Soltani, Maryam Akhtari, Elham Madreseh, Seyedeh Tahereh Faezi, Saeideh Jafarinejad-Farsangi, Ahmadreza Jamshidi, Mahdi Mahmoudi

{"title":"Evaluation of survivin expression and regulating miRNAs of survivin expression in peripheral blood mononuclear cells in systemic lupus erythematous patients.","authors":"Nasim Bolouri, Reza Mansouri, Elham Farhadi, Samaneh Soltani, Maryam Akhtari, Elham Madreseh, Seyedeh Tahereh Faezi, Saeideh Jafarinejad-Farsangi, Ahmadreza Jamshidi, Mahdi Mahmoudi","doi":"10.1177/09612033241276280","DOIUrl":"10.1177/09612033241276280","url":null,"abstract":"Background: Systemic lupus erythematosus is a multisystemic rheumatic disease with different clinical features. Disturbance in apoptosis regulation seems to be a major factor in SLE development.Objective: Survivin plays a key role in mitosis and inhibiting apoptosis. A study was conducted to examine the expression level of survivin and miRNAs that affect survivin transcript levels in patients with SLE.Methods: We isolated peripheral blood mononuclear cells from 50 inactive SLE patients and 50 healthy controls. RNA is extracted and converted to cDNA. The quantitative real-time polymerase chain reaction is conducted to assess the expression levels of survivin total and its variants with effective miRNAs in PBMCs.Results: Expression levels of miR-34a-5p (fold change = 1.5, p++ = 0.027), and 218-5p (fold change = 1.5, p++ = 0.020) were significantly increased. While miR-150-5p (fold change = 0.56, p++ = 0.003) was significantly decreased. The mRNA expression of survivin-WT (fold change = 0.63, p++ = 0.002) was significantly downregulated in SLE patients compared to the healthy controls. Survivin total and its two major variants (survivin-2B, and survivin-ΔEx3) did not differ significantly between SLE patients and controls.Conclusion: Although survivin-TS and its two variants (survivin-2B, and survivin-ΔEx3) were not differently expressed in SLE patients, survivin-WT had altered expression. Despite aberrant miRNA expression in PBMCs from SLE patients, survivin and miRNA expression were not associated with leukopenia. The pathogenesis of SLE disorder might be linked to survivin's other roles in the immune system aside from anti-apoptotic functions.","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1203-1211"},"PeriodicalIF":1.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical significance of serum soluble scavenger receptor CD163 in patients with lupus nephritis. 狼疮性肾炎患者血清中可溶性清道夫受体 CD163 的临床意义。

IF 1.9 4区医学

Lupus Pub Date : 2024-10-01 Epub Date: 2024-08-22 DOI: 10.1177/09612033241276033

Yanjie Liu, Meiyan Li, Huamei Zhang, Zhe Yin, Xiaoli Wang

{"title":"Clinical significance of serum soluble scavenger receptor CD163 in patients with lupus nephritis.","authors":"Yanjie Liu, Meiyan Li, Huamei Zhang, Zhe Yin, Xiaoli Wang","doi":"10.1177/09612033241276033","DOIUrl":"10.1177/09612033241276033","url":null,"abstract":"Background: The soluble CD163 (sCD163) was elevated in systemic lupus erythematosus (SLE) patients.Purpose: To study whether serum sCD163 could be used to predict the occurrence and prognosis of lupus nephritis (LN).Research design: The recruited patients were classified into different groups according to standard identification criteria.Study sample: The patients with LN.Data collection and analysis: 11 indices were analyzed and compared in SLE and LN patients. Furthermore, the level of serum sCD163 was detected using an enzyme-linked immunosorbent assay. Meanwhile, the receiver operating characteristic analysis was performed to evaluate the prediction effect of sCD163. Additionally, spearman correlation analysis of serum sCD163 with indices was conducted.Results: There were six positive indices and one negative risk factor correlated to LN. sCD163 was elevated in LN patients and could be used to diagnose LN. Importantly, sCD163 was increased in LN patients with a heavy SLE disease activity index. Finally, it was revealed that the level of sCD163 was higher in the LN patients with no response than that with complete or partial response, which also could predict the prognosis of LN.Conclusions: Serum sCD163 was elevated in LN patients than in SLE patients, which could be used to predict the occurrence and prognosis of LN.","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1279-1288"},"PeriodicalIF":1.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-SARS-CoV-2 mRNA vaccination among patients living with SLE in Sweden: Coverage and clinical effectiveness. 瑞典系统性红斑狼疮患者接种抗 SARS-CoV-2 mRNA 疫苗：覆盖率和临床效果。

IF 1.9 4区医学

Lupus Pub Date : 2024-10-01 Epub Date: 2024-08-12 DOI: 10.1177/09612033241273052

Arthur Mageau, Julia F Simard, Elisabet Svenungsson, Elizabeth V Arkema

{"title":"Anti-SARS-CoV-2 mRNA vaccination among patients living with SLE in Sweden: Coverage and clinical effectiveness.","authors":"Arthur Mageau, Julia F Simard, Elisabet Svenungsson, Elizabeth V Arkema","doi":"10.1177/09612033241273052","DOIUrl":"10.1177/09612033241273052","url":null,"abstract":"Objectives: To describe the uptake of anti-SARS-CoV2 vaccination in 2021 and investigate vaccine effectiveness in systemic lupus erythematosus (SLE) patients in Sweden.Methods: The cumulative incidence of first anti-SARS-CoV2 vaccination was estimated among SLE patients from the Swedish National Patient Register and matched comparators living in Sweden on January 1, 2021. To assess vaccine effectiveness, we included the individuals who received two doses of anti-SARS-CoV2 mRNA vaccines before year 2022, with no COVID-19 diagnosis code before the 2nd vaccine dose. Hospitalization rates with COVID-19 as main diagnosis during the year after second dose were compared between SLE patients and comparators in multivariable-adjusted marginal Cox models, overall and stratified by immunosuppressive treatment received during the year before second vaccine dose.Results: Vaccination uptake was similar between SLE patients and comparators. By December 2021, 9% of both SLE and comparators had not received any vaccine doses. Among 5585 SLE patients and 37,102 comparators, 11 COVID-19 hospitalizations in the SLE group and 20 in the comparators occurred. SLE was associated with a higher risk of COVID-19 hospitalization (HR = 3.47, 95%CI 1.63-7.39). The HR was higher for immunosuppressive-treated SLE (7.03 95%CI 3.00-16.46) than for immunosuppressive-untreated (1.50 95%CI 0.34-6.60). Vaccination of immunosuppressive-untreated SLE patients had similar effectiveness as comparators.Conclusion: Anti-SARS-CoV2 vaccination coverage was similar between SLE patients and the general population in Sweden. Even though the incidence of post-vaccination COVID-19 hospitalization was very low, vaccine effectiveness was diminished in SLE patients compared to the general population and lowest in those treated with immunosuppressants.","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"1192-1202"},"PeriodicalIF":1.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141971406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lupus最新文献